10% Owner Richard Griffiths Sells 5.48M ADSs for ~$88M
SLN has more than doubled off its 52-week low of $4.19.
Summary
10% owner Richard Griffiths sold 5.48 million ADSs of Silence Therapeutics for approximately $88 million on August 10, 2026, reducing his stake to 7.49 million ADSs.
Key Events · Ownership and Investor Activity · SLN
-
10% Owner Sells 5.48M ADSs
Richard Griffiths sold 5,484,320 ADSs on August 10, 2026, across 11 transactions at prices ranging from $15.58 to $16.35 per ADS.
-
Stake Reduced to 7.49M ADSs
Post-transaction holdings fell to 7,488,660 ADSs, down from approximately 12.97 million ADSs before the sale.
-
Follows Prior $16.3M Sale
This sale comes after Griffiths sold $16.3 million in ADSs in July 2026, as disclosed in a Schedule 13D/A.
-
Sale Coincides with Offering
The sale occurred on the same day the company priced a $175 million underwritten offering at $13.50 per ADS, adding to the supply overhang.
Analysis · SLN · Life Sciences
Controlling shareholder Richard Griffiths sold 5,484,320 American Depositary Shares on August 10, 2026, across 11 transactions at prices between $15.58 and $16.35 per ADS. The sale reduces his post-transaction holdings to 7,488,660 ADSs. This follows a $16.3 million sale disclosed in July and comes just days after the company priced a $175 million underwritten offering at $13.50 per ADS. The sale is significant for a 10% owner and adds to the overhang from the recent capital raises.
At the time of this filing, SLN was trading at $14.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $641.6M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.